Sana Biotechnology, Inc. (SANA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.33-1.69%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sana Biotechnology, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.166
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-0.685
Annual ending 2027-12-31
Revenue	—	6.95M
EPS	—	-0.591

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage cash flow and reduce operating expenses	Management is focused on improving cash flow and cutting expenses despite recent losses.	Intact	Cash from operating activities remains below -$30M per quarter beyond 2026	Cash from operations: $-32.79M FY2026-Q2; GAAP. Published target: Reduce negative cash from operations to less than -$30M per quarter by end 2026. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026-32,790,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management reported cash position increased from $138.4M at 2025-Q4 to $160.5M at 2026-Q2, supported by equity financings including Mayo Clinic investment. Non-GAAP operating cash burn for the six months ended June 30, 2026 was $69.3M, lower than prior year. Cash runway is expected into mid-2027, indicating management is delivering on cash flow and expense management priorities. Delivery assessment Oct 24, 2026
Advance SC451 and SG293 clinical trials	Sana is advancing key clinical trials for SC451 and SG293, aiming for important data points.	Intact	No significant progress or data release on SC451 and SG293 trials by end of 2026	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management consistently emphasized progress toward IND filing and Phase 1/2 trial start for SC451 and clinical study start for SG293 in 2026. Cash position increased from $101.1M in 2026-Q1 to $160.5M in 2026-Q2, supporting development activities. Net loss increased from $47.2M to $63.6M over the same period, reflecting ongoing investment. The trajectory matches management's stated focus on advancing these clinical programs. Delivery assessment Oct 24, 2026
Leverage strategic partnership with Mayo Clinic	The company formed a strategic partnership with Mayo Clinic to boost research.	Improving	No measurable progress or collaboration outcomes from Mayo Clinic partnership by mid-2027	Qualitative: Mayo Clinic partnership executed Apr 2026; no measurable outcomes yet vs mid-2027 target Sana entered strategic stock purchase agreement with Mayo Clinic in April 2026. No news of stalled collaboration outcomes. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The strategic partnership with Mayo Clinic was announced in 2025-Q4 and reiterated through 2026-Q2, including a $25 million equity investment in 2026-Q1. This collaboration aims to accelerate SC451 development and delivery. The partnership remains active and aligned with management's growth strategy. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.59

$-0.58 → $-0.59 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.58	$6,950,000	5 / 6
2026-07-25	$-0.58	$6,950,000	5 / 6
2026-07-26	$-0.58	$6,950,000	5 / 6
2026-07-27	Unavailable	$0	4 / 6
2026-07-28	Unavailable	$0	4 / 6
2026-07-29	Unavailable	$0	4 / 6
2026-07-30	Unavailable	$0	4 / 6
2026-07-31	$-0.58	$6,950,000	5 / 6
2026-08-01	$-0.58	$6,950,000	5 / 6
2026-08-02	Unavailable	$0	4 / 6
2026-08-03	$-0.58	$6,950,000	5 / 6
2026-08-04	$-0.58	$6,950,000	5 / 6
2026-08-05	$-0.58	$6,950,000	5 / 6
2026-08-06	Unavailable	$0	4 / 6
2026-08-08	Unavailable	$0	4 / 6
2026-08-09	Unavailable	$0	4 / 6
2026-08-10	Unavailable	$0	4 / 6
2026-08-12	$-0.58	$6,950,000	5 / 6
2026-08-13	$-0.58	$6,950,000	5 / 6
2026-08-14	$-0.58	$6,950,000	5 / 6
2026-08-15	$-0.58	$6,950,000	5 / 6
2026-08-16	$-0.58	$6,950,000	5 / 6
2026-08-17	$-0.58	$6,950,000	5 / 6
2026-08-18	$-0.58	$6,950,000	5 / 6
2026-08-19	$-0.58	$6,950,000	5 / 6
2026-08-20	$-0.59	$6,950,000	5 / 6
2026-08-21	$-0.59	$6,950,000	5 / 6
2026-08-22	$-0.59	$6,950,000	5 / 6
2026-08-23	$-0.59	$6,950,000	5 / 6
2026-08-24	$-0.59	$6,950,000	5 / 6
2026-08-25	$-0.59	$6,950,000	5 / 6
2026-08-26	$-0.59	$6,950,000	5 / 6
2026-08-27	$-0.59	$6,950,000	5 / 6
2026-08-28	$-0.59	$6,950,000	5 / 6
2026-08-29	$-0.59	$6,950,000	6 / 6
2026-08-30	$-0.59	$6,950,000	6 / 6
2026-08-31	$-0.59	$6,950,000	6 / 6
2026-09-01	$-0.59	$6,950,000	6 / 6
2026-09-02	$-0.59	$6,950,000	6 / 6
2026-09-03	$-0.59	$6,950,000	6 / 6
2026-09-04	$-0.59	$6,950,000	6 / 6
2026-09-05	$-0.59	$6,950,000	6 / 6
2026-09-06	$-0.59	$6,950,000	6 / 6
2026-09-07	$-0.59	$6,950,000	6 / 6
2026-09-08	$-0.59	$6,950,000	6 / 6
2026-09-09	$-0.59	$6,950,000	6 / 6
2026-09-10	$-0.59	$6,950,000	6 / 6
2026-09-11	$-0.59	$6,950,000	6 / 6
2026-09-12	$-0.59	$6,950,000	6 / 6
2026-09-13	$-0.59	$6,950,000	6 / 6
2026-09-14	$-0.59	$6,950,000	6 / 6
2026-09-15	$-0.59	$6,950,000	6 / 6
2026-09-16	$-0.59	$6,950,000	6 / 6
2026-09-17	$-0.59	$6,950,000	6 / 6
2026-09-18	$-0.59	$6,950,000	6 / 6
2026-09-19	$-0.59	$6,950,000	6 / 6
2026-09-20	$-0.59	$6,950,000	6 / 6
2026-09-21	$-0.59	$6,950,000	6 / 6
2026-09-22	$-0.59	$6,950,000	6 / 6
2026-09-23	$-0.59	$6,950,000	6 / 6
2026-09-24	$-0.59	$6,950,000	6 / 6
2026-09-25	$-0.59	$6,950,000	6 / 6
2026-09-26	$-0.59	$6,950,000	6 / 6
2026-09-27	$-0.59	$6,950,000	6 / 6
2026-09-28	$-0.59	$6,950,000	6 / 6
2026-09-29	$-0.59	$6,950,000	6 / 6
2026-09-30	$-0.59	$6,950,000	6 / 6
2026-10-01	$-0.59	$6,950,000	6 / 6
2026-10-02	$-0.59	$6,950,000	6 / 6
2026-10-03	$-0.59	$6,950,000	6 / 6
2026-10-04	$-0.59	$6,950,000	6 / 6
2026-10-05	$-0.59	$6,950,000	6 / 6
2026-10-06	$-0.59	$6,950,000	6 / 6
2026-10-07	$-0.59	$6,950,000	6 / 6
2026-10-08	$-0.59	$6,950,000	6 / 6
2026-10-09	$-0.59	$6,950,000	6 / 6
2026-10-10	$-0.59	$6,950,000	6 / 6
2026-10-11	$-0.59	$6,950,000	6 / 6
2026-10-12	$-0.59	$6,950,000	6 / 6
2026-10-13	$-0.59	$6,950,000	6 / 6
2026-10-14	$-0.59	$6,950,000	6 / 6
2026-10-15	$-0.59	$6,950,000	6 / 6
2026-10-16	$-0.59	$6,950,000	6 / 6
2026-10-17	$-0.59	$6,950,000	6 / 6
2026-10-18	$-0.59	$6,950,000	6 / 6
2026-10-19	$-0.59	$6,950,000	6 / 6
2026-10-20	$-0.59	$6,950,000	6 / 6
2026-10-21	$-0.59	$6,950,000	6 / 6
2026-10-22	$-0.59	$6,950,000	6 / 6
2026-10-23	$-0.59	$6,950,000	6 / 6
2026-10-24	$-0.59	$6,950,000	6 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	8	1
2026-07-01	8	1
2026-08-01	8	1
2026-09-01	8	1
2026-10-01	8	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage cash flow and reduce operating expensesCash from operations: $-32.79M
Advance SC451 and SG293 clinical trialsQualitative condition

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-59.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sana Biotechnology, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative growth, centered on clinical programs rather than established earnings. Management is advancing its stated priorities, but the thesis remains in a watch state and confidence in the overall read is low.

What's priced into Sana Biotechnology, Inc.

The evidence does not provide a valuation level or clear market expectations, so whether SANA is cheap or expensive versus peers cannot be assessed. The priced-in fragility tier is low, with no fragility gates triggered, but that does not resolve the uncertainty around the business outlook.

What the fundamentals likely do

Near term, results remain weak and the company is loss-making. Cash rose to $160.5 million in 2026-Q2, while net loss also increased; management expects cash runway into mid-2027 and is continuing investment in SC451 and SG293. A next-call guidance cut is a key near-term risk, and the evidence flags a meaningful chance of a miss.

What Sana Biotechnology, Inc. hinges on

The multi-year thesis depends on progress toward SC451 and SG293 clinical milestones, alongside continued cash and expense management. Near term, a guidance cut or weaker employment data could pressure the business backdrop, while continued strength from healthcare bellwethers could support sector momentum.